Results 221 to 230 of about 632,185 (263)

An 85-year record of glacier change and refined projections for Kennicott and Root Glaciers, Alaska. [PDF]

open access: yesNat Commun
Wells A   +8 more
europepmc   +1 more source

ROS‐induced modifications of fibrin clots connect immune responses to atherothrombosis in systemic lupus erythematosus

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Cardiovascular events are major determinants of morbidity and mortality in systemic lupus erythematosus (SLE), particularly in patients with renal involvement. While oxidative stress has been implicated in driving vascular and renal damage in SLE, the specific mechanisms remain unclear.
Matteo Becatti   +13 more
wiley   +1 more source

Wild, scenic, and toxic: Recent degradation of an iconic Arctic watershed with permafrost thaw. [PDF]

open access: yesProc Natl Acad Sci U S A
Sullivan PF   +7 more
europepmc   +1 more source

Comparative efficacy and safety of anakinra and canakinumab in patients with VEXAS syndrome – an international multicenter study

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS syndrome. Methods This multicenter international study includes VEXAS patients from France, Israel, and Italy treated with IL1 inhibition (IL1i).
Tali Eviatar   +35 more
wiley   +1 more source

A randomized, placebo‐controlled trial of hydroxychloroquine in incomplete lupus

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity and incidence of SLE. Methods Hydroxychloroquine (HCQ) was chosen as an
Nancy J. Olsen   +14 more
wiley   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell‐Targeted Therapies

open access: yesArthritis &Rheumatology, Accepted Article.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no FDA‐approved disease‐modifying therapies for SjD.
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

National Mortality Databases to Assess Disease Burden in Systemic Autoimmune Diseases: A Valuable Resource, But with Limitations

open access: yesArthritis &Rheumatology, Accepted Article.
Disease‐specific mortality statistics are useful measures of disease burden. Population‐based studies from a few United States counties have reported mortality in systemic autoimmune diseases (SAID). However, due to substantial differences in the population structure of these counties as well as relatively small numbers of SAID deaths in these counties,
Ram Raj Singh
wiley   +1 more source

Diagnostic implications and correlates of plasma ADA2 activity and ADA2 variants

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives Deficiency of adenosine deaminase 2 (DADA2) is a monogenic autoinflammatory disease manifested as polyarteritis nodosa, stroke, and bone marrow failure. Leveraging an international cohort of 200 DADA2 cases, we aimed to characterize the diagnostic utility of a plasma ADA2 enzyme activity assay and understand the implications of residual ADA2
Jian Yue   +55 more
wiley   +1 more source

Community Comfort With Automatic Sharing of Race, Ethnicity, and Language Data Between Health Care Settings: Cross-Sectional Study.

open access: yesInteract J Med Res
Brazer N   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy